- Home
- VBF vs TIL Comparison
VBF vs TIL Comparison
Compare VBF & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBF
- TIL
- Stock Information
- Founded
- VBF 1970
- TIL 2018
- Country
- VBF United States
- TIL United States
- Employees
- VBF N/A
- TIL N/A
- Industry
- VBF Trusts Except Educational Religious and Charitable
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- VBF Finance
- TIL Health Care
- Exchange
- VBF Nasdaq
- TIL Nasdaq
- Market Cap
- VBF 186.1M
- TIL 218.4M
- IPO Year
- VBF N/A
- TIL 2021
- Fundamental
- Price
- VBF $15.67
- TIL $26.50
- Analyst Decision
- VBF
- TIL Buy
- Analyst Count
- VBF 0
- TIL 4
- Target Price
- VBF N/A
- TIL $100.33
- AVG Volume (30 Days)
- VBF 45.5K
- TIL 154.7K
- Earning Date
- VBF 01-01-0001
- TIL 11-13-2024
- Dividend Yield
- VBF 5.18%
- TIL N/A
- EPS Growth
- VBF N/A
- TIL N/A
- EPS
- VBF N/A
- TIL N/A
- Revenue
- VBF N/A
- TIL N/A
- Revenue This Year
- VBF N/A
- TIL N/A
- Revenue Next Year
- VBF N/A
- TIL $2.64
- P/E Ratio
- VBF N/A
- TIL N/A
- Revenue Growth
- VBF N/A
- TIL N/A
- 52 Week Low
- VBF $13.68
- TIL $6.08
- 52 Week High
- VBF $16.27
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- VBF 24.13
- TIL 38.29
- Support Level
- VBF $16.10
- TIL $24.31
- Resistance Level
- VBF $16.38
- TIL $37.24
- Average True Range (ATR)
- VBF 0.22
- TIL 4.02
- MACD
- VBF -0.03
- TIL 0.26
- Stochastic Oscillator
- VBF 5.16
- TIL 10.85
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.